Peak Pharmaceuticals, Inc. announced unaudited earnings results for the third quarter and nine months ended June 30, 2015. For the quarter, the company reported revenues of $317,244. Net loss was $488,483 against $1,630,090 a year ago. All revenues were earned from sales of the company's Canna-Pet line of products.

For the nine months, the company reported revenues of $751,313. Net loss was $1,893,779 against $2,492,464 a year ago.